Sort by

Send to

Choose Destination

Search results

Items: 4


Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals.

Blazkova J, Refsland EW, Clarridge KE, Shi V, Justement JS, Huiting ED, Gittens KR, Chen X, Schmidt SD, Liu C, Doria-Rose N, Mascola JR, Heredia A, Moir S, Chun TW.

J Clin Invest. 2019 Nov 1;129(11):4832-4837. doi: 10.1172/JCI125955.


An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals.

Sneller MC, Clarridge KE, Seamon C, Shi V, Zorawski MD, Justement JS, Blazkova J, Huiting ED, Proschan MA, Mora JR, Shetzline M, Moir S, Lane HC, Chun TW, Fauci AS.

Sci Transl Med. 2019 Sep 11;11(509). pii: eaax3447. doi: 10.1126/scitranslmed.aax3447. Epub 2019 Sep 5.


Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection.

Huiting ED, Gittens K, Justement JS, Shi V, Blazkova J, Benko E, Kovacs C, Wender PA, Moir S, Sneller MC, Fauci AS, Chun TW.

J Infect Dis. 2019 Jun 19;220(2):270-274. doi: 10.1093/infdis/jiz100.


Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.

Clarridge KE, Blazkova J, Einkauf K, Petrone M, Refsland EW, Justement JS, Shi V, Huiting ED, Seamon CA, Lee GQ, Yu XG, Moir S, Sneller MC, Lichterfeld M, Chun TW.

PLoS Pathog. 2018 Jan 11;14(1):e1006792. doi: 10.1371/journal.ppat.1006792. eCollection 2018 Jan.

Supplemental Content

Loading ...
Support Center